首页> 美国卫生研究院文献>Bentham Open Access >Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
【2h】

Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence

机译:白藜芦醇和临床试验:从体外研究到人类证据的十字路口

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a non-flavonoid polyphenol that may be present in a limited number of food-stuffs such as grapes and red wine. Resveratrol has been reported to exert a plethora of health benefits through many different mechanisms of action. This versatility and presence in the human diet have drawn the worldwide attention of many research groups over the past twenty years, which has resulted in a huge output of in vitro and animal (preclinical) studies. In line with this expectation, many resveratrol-based nutraceuticals are consumed all over the world with questionable clinical/scientific support. In fact, the confirmation of these benefits in humans through randomized clinical trials is still very limited. The vast majority of preclinical studies have been performed using assay conditions with a questionable extrapolation to humans, i.e. too high concentrations with potential safety concerns (adverse effects and drug interactions), short-term exposures, in vitro tests carried out with non-physiological metabolites and/or concentrations, etc. Unfortunately, all these hypothesis-generating studies have contributed to increased the number of ‘potential’ benefits and mechanisms of resveratrol but confirmation in humans is very limited. Therefore, there are many issues that should be addressed to avoid an apparent endless loop in resveratrol research. The so-called ‘Resveratrol Paradox’, i.e., low bioavailability but high bioactivity, is a conundrum not yet solved in which the final responsible actor (if any) for the exerted effects has not yet been unequivocally identified. It is becoming evident that resveratrol exerts cardioprotective benefits through the improvement of inflammatory markers, atherogenic profile, glucose metabolism and endothelial function. However, safety concerns remain unsolved regarding chronic consumption of high RES doses, specially in medicated people. This review will focus on the currently available evidence regarding resveratrol’s effects on humans obtained from randomized clinical trials. In addition, we will provide a critical outlook for further research on this molecule that is evolving from a minor dietary compound to a possible multi-target therapeutic drug.
机译:白藜芦醇(3,5,4'-三羟基-反式-二苯乙烯)是一种非类黄酮多酚,可存在于有限的食品中,例如葡萄和红酒。据报道,白藜芦醇可通过许多不同的作用机制发挥许多健康益处。在过去的20年中,人类饮食中的这种多功能性和存在吸引了许多研究小组的全球关注,这导致了体外和动物(临床前)研究的巨大成果。符合这一期望,在世界范围内,许多基于白藜芦醇的保健食品在可疑的临床/科学支持下被消费。实际上,通过随机临床试验对人类这些益处的确认仍然非常有限。绝大多数的临床前研究都是使用对人类有可疑推断的测定条件进行的,即浓度过高而潜在的安全隐患(不良影响和药物相互作用),短期暴露,使用非生理代谢物进行的体外试验不幸的是,所有这些假说产生的研究都为增加白藜芦醇的“潜在”益处和机理做出了贡献,但在人类中的确证非常有限。因此,有许多问题需要解决,以避免白藜芦醇研究中出现明显的循环。所谓的“白藜芦醇悖论”,即生物利用度低但生物活性高,是一个尚未解决的难题,尚未明确确定发挥作用的最终责任方(如果有)。越来越明显的是,白藜芦醇通过改善炎症标记,动脉粥样硬化,葡萄糖代谢和内皮功能发挥了心脏保护作用。但是,关于长期服用高RES剂量的安全性问题仍未解决,特别是在有药的人群中。这项审查将侧重于从随机临床试验中获得的有关白藜芦醇对人体影响的现有证据。此外,我们将对该分子的研究进行进一步的展望,该分子正在从微量饮食化合物发展成为可能的多靶点治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号